
Today we’re sharing a defining moment for Cellular Intelligence. We have entered into an agreement with @novonordisk to acquire STEM-PD, a Phase 2-ready allogeneic cell therapy program for Parkinson’s disease. Alongside the acquisition, Novo Nordisk is making a strategic investment in Cellular Intelligence. This is one of the most advanced cell therapy programs in Parkinson’s. The program has an FDA-cleared IND for Phase 2 and Fast Track Designation, following completion of Phase 1/2 dosing in the underlying academic clinical program, STEM-PD. This is more than an asset acquisition. It marks the beginning of an AI-native era for cell replacement therapy. One where biology is no longer destiny, but design. Read all about it here: cellularintelligence.com/ste… #CellTherapy #ParkinsonsDisease #Biotech #AIinBiotech #TechBio STEM-PD is an investigational therapy; its safety and efficacy have not been established.








